Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 10, 2026
The role of S100A8/A9 in the pathogenesis of acute exacerbations of pulmonary fibrosisNaoki Nakamura, Hisao Higo, Satoru Senoo, et al.
Molecular Oncology|April 8, 2017
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivoKenichiro Kudo, Kadoaki Ohashi, Go Makimoto, et al.
Biochemical and Biophysical Research Communications|September 5, 2020
Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutationsHiroe Kayatani, Kadoaki Ohashi, Kiichiro Ninomiya, et al.
Thoracic Cancer|May 3, 2024
Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case reportHiroaki Matsuura, Hisao Higo, Tadahiro Kuribayashi, et al.
Journal of Clinical Medicine|August 26, 2023
Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective StudyHisao Higo, Hirohisa Ichikawa, Yukako Arakawa, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve <i>Egfr</i>-Mutant Lung Cancer with Non-Inflamed Tumor MicroenvironmentAtsuko Hirabae, Tadahiro Kuribayashi, Shuta Tomida, et al.
Internal Medicine (Tokyo, Japan)|September 11, 2024
Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation SuspensionTaichi Ozeki, Hisao Higo, Hiroki Omori, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2025
The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)Kakuhiro Yamaguchi, Shun Takao, Nobuhiro Kanaji, et al.
Respiratory Research|February 8, 2022
Identification of targetable kinases in idiopathic pulmonary fibrosisHisao Higo, Kadoaki Ohashi, Shuta Tomida, et al.
Plos One|August 28, 2020
Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysisSatoru Senoo, Nobuaki Miyahara, Akihiko Taniguchi, et al.
Pageof 5